Results: From September 2011 to December 2013, 80 patients were enrolled and two patients withdrew consent, finally 78 patients included for analysis. There were 73 male and 5 female. There were 96.2% of them had 0-1 WHO ECOG. For the primary site, 23 (29.5%) patients were oral cavity, 26 (33.3%) patients were oropharynx, 24 (30.8%) patients were hypopharynx, and 5 (6.4%) patients were larynx. Treatment compliance was well. There were 92.3% patients completed planned schedule. After the induction chemotherapy, the overall response rate was 92.3%, which included 37.2% complete response and 55.1% partial response, respectively. Only 2(2.6%) patients had stable disease and 1(1.3%) patient had progression disease. The response rate of oral cavity, oropharynx, hypopharynx, and larynx were 82.6%, 93.2%, 100%, and 100%, respectively. There were 47.4% grade 3 or 4 neutropenia and 20.5% grade 3 anemia. Only 6 severe adverse event were report, including 4 febrile neutropenia with sepsis, one osteomyelitis, and one massive bleeding.

Conclusion: This outpatient docetaxel-based neoadjuvant chemotherapy regimen is a effective regimen in locally advanced squamous cell carcinoma of head and neck.

EP-1107 Impact of waiting time for treatment initiation on giotic T1N0M0 squamous cell carcinoma RT results

A. Mucha-Malecka1, K. Urbanek1, A. Chrostowska1, K. Malecki1, P. Hebdza1, J. Jakubowicz1

1'Center of Oncology, Head and Neck Department, Krakow, Poland

Purpose or Objective: The goal of this study is to evaluate the results of treatment of T1N0M0 glottic cancer with irradiation, with emphasis on the influence of time from diagnosis to the beginning of radiation therapy.

Material and Methods: We performed the retrospective analysis of the group of 539 patients with T1N0M0 glottic cancer, treated with radiation therapy in the Center of Oncology in Krakow between years 1977 and 2004. In 481 cases (89%) the tumor was limited to single vocal cord and in the remaining 58 involved both of them. Anterior commissure involvement was observed in 173 (32%) of the patients. According to the radiotherapy technique and fractionation schedule, we have divided patients into three separate groups: I - two oblique fields, TD 60 Gy/24-277 patients (51%); II - two opposite fields, TD 60 Gy/30 - 160 (31%); III - one lateral photon-electron beam, TD 60 Gy/30 - 102 (19%). The average time from laryngeal biopsy to the beginning of radiotherapy was 56 days (range: 3-145 days). The overall survival (OS) and disease-free survival (DFS) were calculated using the Kaplan - Meier method. Log rank test was used to calculate differences between each groups, and the independent prognostic factors were selected by the Cox multiparameter analysis.

Results: The 5-year OS and 10-year OS were 84% and 69%, 5- and 10-year DFS were 90% and 88%, and the 5- and 10-year LC rates were 89% and 87%, respectively. One-dimensional analysis revealed following prognostic factors for LC and DFS: tobacco smoking, radiotherapy technique, and the anterior commissure involvement. The 5- and 10-year LC rates were observed in the group treated with oblique beams (80% and 78%, respectively), and the highest when the oblique fields were used - 91% and 88%, respectively (p=0.002). The tumor involvement of the anterior commissure decreased 5-year LC by 15% (92 to 77%), and 10-year LC rate by 19% (89 to 70%, respectively, p=0.000). The waiting time for the beginning of RT longer than 30 days from the biopsy was statistically significant poor prognostic factor for DFS and LC. 5- and 10-year LC rates in the group of patients who started RT during the period of 30 days from the biopsy were 92% and 90%, respectively, and in the group which started treatment after that time, these LC rates were 84% and 82%, respectively (p=0.01). Tumor interior commissure involvement was proven to be an independent prognostic factor affecting DFS and LC.

Conclusion: The aim of the present study is to analyze clinical outcomes and toxicity in patients with locoregionally advanced head and neck carcinoma treated with concurrent hyperfractionated radiotherapy with Cetuximab and Carboplatin.

Material and Methods: Forty-one patients (8 cases ST.III and 33 cases ST.IV) were prospectively included in this study from September 2009 to November 2014. Radiotherapy consisted in hyperfractionated radiotherapy: 1.15-1.20 Gy/fraction, BID, 5 days/week during 7 weeks. The average dose administered was 80.2 Gy (79.2-80.5). Carboplatin was administered 5 mg/m2 before each fraction of radiotherapy. Cetuximab was administered 400 mg/m2 one week before hyperfractionated radiotherapy and then 250 mg/m2 weekly while radiotherapy. Seven patients were not evaluable for response (in 3 patients, Capecitabine was added to the treatment; in 1 patient nodal metastases came from a papillary thyroid carcinoma; 3 patients were not evaluable for response because 2 patients died within 30 days after treatment and 1 patient has not enough follow-up to be evaluated for response).

Results: All but 2 of the 34 evaluable patients showed objective response (19 complete responses). The local relapse-free survival, cause specific survival, and overall survival was 58.7%, 57%, 49% at 5 years, respectively. Severe (Grade II/III) acneiform rash resulted predictive of Clinical Response (p=0.005), Local relapse (p=0.008), distant metastases (p=0.012) and tumour related dead free survival (p<0.0001). Severe (Grade III) acute cutaneous and mucosal toxicity was present in almost 60% of the cases.

Conclusion: This protocol induces a high rate of clinical responses and excellent survival figures in patients developing an strong immune response after combined radiochemoimmunotherapy.